HALO

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Halozyme Therapeutics, Inc. on May 1, 2025. The filing details the voting results for three proposals presented to shareholders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.

Material Changes and Voting Results

As of the record date, there were 123,533,310 shares of common stock outstanding. A total of 112,767,003 shares were represented at the meeting. All three proposals were approved:

• Proposal 1 (Election of Directors): Jeffrey W. Henderson and Helen I. Torley were elected as Class III directors for a three-year term.
• Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved.
• Proposal 3 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

Voting Breakdown

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

• Verify the definitive proxy statement filed on March 18, 2025, for detailed background on the director nominees and executive compensation.
• Note that approximately 10.4 million shares were subject to broker non-votes on the director and compensation proposals.
• Confirm the term expiration for the newly elected directors is set for the 2028 Annual Meeting.